Chalk another one up for Bristol Myers Squibbs psoriasis drugthe TYK2 inhibitor outshone placebo and Amgens Otezla in a second phase 3 study, teeing up discussions with regulators.<\/p>\n
The study, known as POETYK PSO-2, tested the drug, deucravacitinib, against placebo and Otezla in 1,020 patients with moderate to severe plaque psoriasis, the company said in a statement. After 16 weeks of treatment, significantly more patients taking Bristol Myers drug than placebo had a 75% reduction of psoriasis area and severity and clear or almost clear skin as measured by the static Physicians Global Assessment, a visual assessment of psoriasis.<\/p>\n
In addition to meeting these co-primary endpoints, deucravacitinib also beat Otezla on these measures, hitting key secondary endpoints.<\/p>\n
Blazing a Trail to Clinical Trial Diversity: Four-Part Webinar Series from Syneos Health, Featuring Pharma, Clinical Research and Community Health Leaders <\/p>\n
This series will identify obstacles that stifle appropriate patient diversity in trials; unpack the organizational overhaul needed; share how sponsors, patients & investigators have come together to overcome hurdles; and explore how policy innovations can move the industry forward. <\/p>\n
RELATED: Bristol Myers' psoriasis drug beats Amgen rival in phase 3<\/p>\n
The company reported the results in broad strokes with plans to present detailed data at a future medical meeting. The news comes three months after Bristol Myers reported a similar performance in the 666-patient POETYK PSO-1 study, in which deucravacitinib also outperformed placebo and Otezla.<\/p>\n
The superior efficacy we have observed in patients with moderate to severe psoriasis, combined with the well-tolerated safety profile, are consistent with the novel mechanism of action of deucravacitinib, a potential new class of molecule, said Samit Hirawat, M.D., chief medical officer of Bristol Myers Squibb.<\/p>\n
Deucravacitinib works by blocking TYK2, an enzyme involved in the IL-12, IL-12 and type 1 IFN pathways, which play a role in psoriasis and other immune-mediated diseases. Bristol Myers is developing the drug for psoriatic arthritis, lupus and inflammatory bowel disease.<\/p>\n
<\/p>\n
Read the original post: Chalk another one up for Bristol Myers Squibbs psoriasis drugthe TYK2 inhibitor outshone placebo and Amgens Otezla in a second phase 3 study, teeing up discussions with regulators. Continue reading
\nBristol Myers' psoriasis drug strikes again, beating Amgen's Otezla in a 2nd pivotal trial - FierceBiotech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"